Elm Street Ventures, based in New Haven, Connecticut, is a venture fund founded in 2006. They focus on Seed to Series D stages, with a portfolio including companies like Cybrexa Therapeutics and Device42. Elm Street Ventures specializes in BioTech, Pharmaceuticals, Healthcare, Apps, Big Data & Analytics, Information Technology, and Software sectors. The fund, led by partner Robert Bettigole, has made 24 investments and has seen 7 successful exits. Elm Street Ventures' primary strategy involves creating and operating life sciences companies based on intellectual property developed at Yale University. For more information, visit their website at www.elmvc.com.